In the latest episode of Vantage Point Podcast, I sat down with Sam Watson, MD of Bioxyne (BXN:ASX), to unpack how the company is positioning itself at the intersection of medicinal cannabis, psychedelics, and precision medicine.
We covered a fair bit:
→ Why GMP certification isn’t just a compliance checkbox — it’s a genuine competitive moat
→ The shift toward finished product formats (inhalables, pastilles) and what the market is actually asking for
→ The emerging opportunity in psilocybin and MDMA for depression and PTSD
→ Bioxyne’s strategy for commercialising investigational medicines earlier to accelerate growth while managing risk
This is one of the fastest-growing sectors in healthcare — and Bioxyne is one of the few ASX-listed names that’s doing it profitably.
Spotify: https://open.spotify.com/episode/2Spuo10pGxvffJuORrTCxw?si=h4u_u_l0SeWxZT-cHT0zdg
YouTube: https://youtu.be/PNFQAydFIDo?si=4AStoe_ah7vYae0T